Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug in the treatment of moderately to severely active ulcerative colitis (UC), making it the first biologic therapy available in the region to selectively target the IL-12/IL-23 pathway.
Specifically, the therapy is now indicated in adults who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
